



FoundationOne® Liquid CDx Patient Report Guide

FoundationOne Liquid CDx is a liquid biopsy test, ordered by your doctor, that looks for mutations and biomarkers in your cancer's DNA, using your blood sample. The results of this test can help you and your doctor decide together on the next best step in your treatment plan. This report guide can help prepare you to review and discuss your test results with your doctor.

How to use this guide:

- Use this guide *after* your results are ready.
- You can request a copy of your FoundationOne Liquid CDx report by contacting our Client Services team at 888-988-3639 or emailing client.services@foundationmedicine.com.
- This guide will walk you through each section, focusing on the first two pages of your report, with numbers to call out different parts of the report.
- The report images in this guide are from a sample report, which can help you read your actual report. This guide does not contain your actual report. Your report may have a different length of pages from the sample report, which may cause some sections of your report to land on different pages from the sample report.
- A **GLOSSARY** of key terms is included on the last page of this guide.

Report Page One

The first page of your report contains a summary of the gene mutations and biomarkers found by testing your sample.

1

Biomarker Findings

High microsite instability (MSI-H) and blood tumor mutational burden (bTMB) are two biomarkers that can help your doctor understand what immunotherapy treatment options might be available for you.

2

Genomic Findings

This section shows the gene mutations that may be linked with treatment options. This includes the names of genes where a mutation was found (e.g., "PIK3CA") along with a description of that mutation (e.g., "E545K").

3

Report Highlights

This provides the highlights from your results, at a glance, to help your doctor focus on the key actionable results for treatment planning.

If your report mentions that you have positive companion diagnostic (CDx) findings, these are described in more detail in the later pages of the report. This refers to an additional layer of results. However, all of your test findings and treatment options are described in the first summary section.



<p>1 Biomarker Findings</p> <p>_____</p> <p>_____</p>	<p>3 Report Highlights</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p>
<p>2 Genomic Findings</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p>	

BIOMARKER FINDING DETAILS

THERAPY + CLINICAL TRIAL IMPLICATIONS



Key Terms

Alterations

Changes in the DNA that can influence cancer growth (also called “mutations”).

Biomarker

A marker found in blood or tissues that may provide your doctor with information about potential treatment options. For example, the status of certain biomarkers can predict response to immunotherapy.

Biomarker Findings

On your FoundationOne Liquid CDx report, the “Biomarker Findings” section includes the following biomarkers: microsatellite instability (MSI) and blood tumor mutational burden (bTMB). A high level of either of these two biomarkers may indicate that you could benefit from immunotherapy. Please note, however, that in other contexts, “biomarkers” may also include gene mutations.

Biomarker Testing

You may also hear the testing referred to as genomic testing, tumor testing, molecular testing, next-generation sequencing (NGS), and genomic profiling. Biomarker testing is a general category of testing that looks for mutations in cancer genes to identify potential treatment options. Foundation Medicine performs a type of biomarker testing called comprehensive genomic profiling (CGP).

Blood Tumor Mutational Burden (bTMB)

A biomarker that can be detected from your blood sample and that may help predict response to immunotherapy. bTMB is a measure of the frequency of mutations in your circulating tumor DNA (ctDNA) when performing FoundationOne Liquid CDx.

Cells

Basic units that make up your body.

Circulating Tumor DNA (ctDNA)

Small DNA fragments that have come from your tumor and can be found circulating in your blood.

Clinical Trial

A type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.

Companion Diagnostic (CDx)

A medical device which provides information essential for the safe and effective use of a corresponding therapy. The test helps doctors determine if a particular treatment’s benefits to a patient will outweigh any potential risks.

Comprehensive Genomic Profiling (CGP)

A method of cancer testing that can find the mutations in your DNA that may be causing your cancer to grow. This is the type of testing performed by Foundation Medicine.

ctDNA Tumor Fraction

An estimate of the percentage of DNA found in your blood sample that is tumor DNA.

DNA

The molecules inside cells that carry genetic information and pass it from one generation to the next. DNA instructs cells how to grow and divide; DNA mutations may lead to cancer growth.

Food and Drug Administration (FDA)

The official US government agency responsible for review and approval of drugs and certain diagnostic tests to determine their safety and effectiveness for the intended use in patients.

Foundation Medicine

Company that performs biomarker/genomic testing called comprehensive genomic profiling (CGP).

FoundationOne Liquid CDx

A next-generation sequencing test developed by Foundation Medicine that analyzes over 300 genes and biomarkers detected in your blood to identify potential treatment options for advanced cancer patients with solid tumors.

Genes

Segments of DNA. Genomic testing may find mutations in genes that can influence cancer growth.

Genomic Findings

Mutations identified in your cancer’s DNA that may be matched with targeted treatment options.

Genomic Testing

You may also hear the testing referred to as biomarker testing, tumor testing, molecular testing, next-generation sequencing (NGS), and genomic profiling. Genomic testing is a general category of testing that looks for mutations in cancer genes to identify potential treatment options. Foundation Medicine performs a type of genomic testing called comprehensive genomic profiling (CGP).

Immunotherapy

A type of cancer treatment that helps the body’s immune system attack cancer cells.

Liquid Biopsy

This type of testing is performed on a blood sample instead of a tissue sample. It looks at DNA from your tumor that is circulating in your blood.

Microsatellite Instability (MSI)

A biomarker that may help predict benefit from immunotherapy. MSI refers to a type of instability in a tumor’s DNA.

Mutations

Changes in the DNA that can influence cancer growth (also called “alterations”).

Targeted Therapy

A type of cancer treatment that attacks cancer cells with specific gene mutations.

Tumor

A mass within the body caused by abnormal growth of cells.

Tumor Type

The type of cancer (e.g., lung cancer, breast cancer, etc.).

FoundationOne® Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. When considering eligibility for certain therapies for which FoundationOne Liquid CDx is a companion diagnostic, testing of plasma is only appropriate where tumor tissue is not available. Patients who are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.FILCDxLabel.com.